A new trial highlights that the timing of chemoradiation and immunotherapy is crucial when treating limited-stage small cell ...
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...
The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...
Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback